Company intelligence / Profile preview
FasT Biopharma
Aston Rowant, Oxfordshire, United Kingdomfastbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
FasT Biopharma’s lead program is a humanized anti-FasL antibody (FBP002) aiming to prevent T cell death, particularly to address checkpoint inhibitor resistance in cancer. Clinical results not yet reported (pre-clinical stage).
- Therapeutic areas
- OphthalmologyEndocrinologyGastroenterologyInfectious DiseasesPulmonologyOncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on FasT Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FasT Biopharma.